In This Issue of the AHPA Report

Total Page:16

File Type:pdf, Size:1020Kb

In This Issue of the AHPA Report The Official Publication of the American Herbal Products Association June 2010 www.ahpa.org Volume 25, Number 6 In this issue of the AHPA Report You Need to Know 2 • New Members • Upcoming AHPA Seminar: cGMP Compliance Series: Meeting Specifications __ Establishing Identity & Vendor Qualification Special Topics 4 • Health Claims Ruling a Win for First Amendment and Commercial Speech by Anthony L. Young, Esq., Partner, Kleinfeld Kaplan & Becker and AHPA General Counsel • NOP Responds to NOSB Recommendation for National Organic Personal Care Standard by Katia Fowler, Director of Communications, American Herbal Products Association Legal & Regulatory 7 • Senators Hatch, Harkin Introduce “Dietary Supplement Full Implementation and Enforcement Act of 2010” • GAO Report Finds Heavy Metals in Herbal Supplements at Levels That Do Not Raise Safety Concerns for FDA • Warning Letter Review FDA’s First cGMP Warning Letter Goes to Herbal Supplement Manufacturer By Anthony L. Young, Esq., AHPA General Counsel Animal Supplements (NOT) and Drug Claims for Supplements By Anthony L. Young, Esq., AHPA General Counsel • Quick Round Up Communications Update 11 • AHPA Media Scan: Notable “herbal headlines” and “AHPA in the News” Calendar of Botanical Events 13 Botanical Science Update 16 • Meetings Attended Oxford’s International Conference on the Science of Botanicals You Need to Know New Members TOPICS: Mr. Young will explain the relevant cGMP regula- tions and their background as well as how FDA has addressed Nature’s Wonder Naturopathic Our office offers a profes- Vendor Qualification and Material Handling in inspections sional dynamic set of adjunctive services in our community to date. He will also describe how manufacturers should ad- with a practice that is limited to alternative and complementary dress issues such as indemnification and out of specification medicine consulting and research. We specialize in Naturopathic materials in their contracts with suppliers. Consulting and Research Biofeedback, Nutrition, and Electro Physiological Reactive measures. We are the area’s Steven Dentali, Ph.D. - Chief Science Officer, AHPA: A natural only Board Certified Naturopath (CTN) with certifications products chemist with a focus on botanicals, Dr. Dentali has been with 15 years experience along with over 30 years experience with AHPA for over 8 years and has worked in the natural products in paramedicine. Website: www.natwonders.com/ industry for 20 years. TOPICS: Dr. Dentali will explain the specific requirements Upcoming AHPA Seminar: regarding establishing the identity of your dietary ingredi- cGMP Compliance Series: Meeting ents, discuss and define regulatory terms such as “scientifi- Specifications – Establishing Identity cally valid method” and “fit for purpose”, provide background & Vendor Qualification on how to determine what method or methods to use to es- tablish identity, identify resources, and review the skills/ On June 17, AHPA’s tele-seminar cGMP Compliance Series: training required for analysts conducting identity testing. Meeting Specifications – Establishing Identity & Vendor Qualification will contain presentations from industry experts who will provide Margaret King, Senior Director QA/QC, Metagenics: With over detailed and practical information on how dietary supplement com- 20 years of industrial experience in QA/QC, laboratory, manufac- panies can address the GMP in regards to identity and vendor quali- turing, facility inspections, validations, and product development of fication – two of the most burdensome and yet nebulous aspects of natural products, Ms. King is responsible for compliance with the regulations. cGMP and International regulations for the company’s US and Belgium manufacturing facilities, as well as for liaison with regula- Whether your company uses whole herbs, cut herbs, powders, or tory agencies at Metagenics. She has also developed the company’s liquids/extracts as components/dietary ingredients, you shouldn’t overall quality management system for meeting FDA’s cGMP com- miss this opportunity to learn what these highly successful compa- pliance regulations. nies and individuals have done to meet the DS-GMP requirements. TOPICS: Ms. King will provide practical information on the usage of an outside (3rd party) lab for identity testing & Presenters & Key topics to be covered: other related considerations, including defining the scope of Tony Young, Esq. - Partner, Kleinfeld, Kaplan & Becker: AHPA testing/methods, contractual arrangements, timelines, QA General Counsel Tony Young has over 35 years experience practic- involvement, pitfalls & benefits of 3rd party testing, OOS or ing food and drug law and counseling clients on compliance with non-conforming issues, and usage of 3rd party labs as part of FDA requirements. a vendor qualification program. The AHPA Report, the official voice of the American AHPA Staff Send inquiries, comments or requests to: Herbal Products Association (AHPA), is published monthly as a service to AHPA members and friends Michael McGuffin, President American Herbal [email protected] of the herbal products industry. The material Products Association contained in this publication is for the information Steven Dentali, PhD, Chief Science Officer 8630 Fenton Street, Suite 918 of AHPA members. Although the information [email protected] Silver Spring, MD 20910 is believed to be correct, AHPA disclaims all Devon Powell, Chief Operations Officer Phone: 301-588-1171 responsibility for any damage or liability that [email protected] Fax: 301-588-1174 may result from any reliance on the information Email: [email protected] contained in this publication. Katia Fowler, Director of Communications [email protected] Website: www.ahpa.org Articles may not be reproduced or reprinted without written permission from AHPA. © copyright 2010, AHPA June 2010 • Page 2 Angela Kwong, Quality Manager, Traditional Medicinals: Ms. REGISTRATION DEADLINE: Wednesday, June 16, 2010 Kwong is responsible for the implementation of DS-GMP at TELE-CONFERENCE SEMINAR DATE/TIME: Traditional Medicinals, and has over 20-plus years of experience Thursday, June 17, 2010 from 1-3pm EST with biopharmaceutical companies specifically in drug develop- REGISTRATION INFO: ment, quality systems, clinical and commercial manufacturing. In Secure internet registration by clicking the link above these roles, Ms. Kwong was frequently charged with the selection COST & GENERAL: and management of key contract suppliers for both API’s and paren- teral drug products. Over the years, she has built strong, positive re- $195 per line for AHPA member companies (unlimited participants!) lationships and successfully managed both US and international suppliers. $495 for non-members Includes an unedited transcript (to review later & for TOPICS: Ms. Kwong will discuss the critical components of training libraries) developing a strong supplier management program. Includes one Certification of Completion (for training and Rupa Das, Vice President of Global Quality & Compliance, BI personnel files) Nutraceuticals: Ms. Das has over 15 years of Quality and Regulatory Additional certificates available – $25 each (for training and Compliance management experience in the Dietary Supplement personnel files) and Personal Care Product Industries. She was key in the develop- Optional CD recording available – $25 (great for your ment and implementation of quality programs such as Identilok® training library) and the global vendor qualification program which assures high quality botanical ingredients to the market. AHPA’s tele-seminars are a convenient and cost-effective way to explore issues, gain insight, and enhance knowledge on what’s TOPICS: Ms. Das will provide information on vendor qual- important to your business. You will be provided with practical, ification from the perspective of the supplier, with a focus on useful documents and information and the opportunity to have common mistakes manufacturers make in their programs your particular questions answered by the experts. Please note, the and efforts, as well as discuss OOS issues. registration fee is charged per phone connection, but as many staff REGISTER ONLINE https://connect.computility.com/form/index. members as you wish may be conferenced in or listen in on your php?id=b2c61eb446a96337fed92f51460e76c1) speaker phone. June 2010 • Page 3 Special Topics application of that statute ran afoul of the First Amendment which Mr. Emord sought to be applied because FDA set standards for Health Claims Ruling a Win for First health claims too high. Amendment and Commercial Speech In this decision, the District Court parsed the scientific data to cut By Anthony L. Young, Esq., Partner, Kleinfeld Kaplan & Becker and through what it characterized as conclusory and unexplained evalu- AHPA General Counsel ations by FDA. FDA cannot deny a health claim where a disclaimer would work. And like many administrative law cases, the District On the one hand, you would think that Jonathan Emord, the attor- Court sends the case back to FDA to consider in light of its decision. ney who has championed the First Amendment in FDA’s evaluation Back to the briar patch goes the claim, to be considered in light of of health claims, would have tired at his Don Quixote-like efforts to another good First Amendment commercial speech decision. And get his clients health claims through FDA’s keyhole. Similarly, you in the news, Jonathan Emord promised he would seek to have FDA would think that FDA (the Bill of Rights here starts
Recommended publications
  • Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry
    molecules Article Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry Dasom Shin, Hui-Seung Kang *, Hyungsoo Kim and Guiim Moon New Hazardous Substances Division, Department of Food Safety Evaluation, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Cheongju 28159, Korea; [email protected] (D.S.); [email protected] (H.K.); [email protected] (G.M.) * Correspondence: [email protected] Received: 11 August 2020; Accepted: 17 September 2020; Published: 24 September 2020 Abstract: In this work, liquid chromatography–tandem mass spectrometry (LC-MS/MS) method was developed and validated for screening and confirmation of 64 illicit compounds in dietary supplements. The target compounds were illegally used pharmaceutical drugs, prohibited compounds, and not authorized ingredients for different therapeutics (sexual enhancement, weight loss, muscular strengthening, and relaxing products). The validation procedure was performed to evaluate selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision according to the Association of Official Analytical Chemists guidelines. The linearity was >0.98 in the range of 1 1 0.5–200 µg L− . The LOQs were in the range 1–10 µg kg− for all target compounds. The accuracy (expressed as recovery) was 78.5–114%. The precision (expressed as the relative standard deviation) was below 9.15%. The developed method was applied for the determination of illicit compounds in dietary supplements collected from websites. As a result, the total detection rate was 13.5% (27 samples detected in 200 samples). The concentrations of detected samples ranged from 0.51 1 to 226 mg g− .
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Herbals, Complementary Medicines & Nutritional Supplements (PDF)
    Herbals, Complementary Medicines Nutritional & Supplements Complementary medicines and nutritional supplements are a popular addition to “traditional” medicine. Information about these therapies can range from news reports and magazine articles to advertising that may contain false claims. This pamphlet was designed to provide veterans and their families with unbiased information. The information in this pamphlet is not intended to take the place of advice from your healthcare provider. Angela Paniagua, Pharm.D., CGP Pharmacy Program, Clement J. Zablocki VAMC Milwaukee, WI Complementary medicines and nutritional supplements are not miracle cures. Do not stop taking your prescription medicine without speaking to your health care provider. Doing so may be dangerous to your health. Warning Several complementary medications have been found to be unsafe and/or unpure. All patients should avoid: 5-HTP DHEA Shark Cartilage Bee Venom L-tryptophan What is herbal therapy? Herbs have been used in medicine for as long as people have been on earth. The use of herbal therapies has been recorded in ancient Greece, Egypt, Rome, India, Russia, and China. Many modern medicines came from Native American remedies. There are many examples of drugs used today that are from plants. They may come from the plant's leaves, roots, flowers or fruits. Digoxin is a good example of a drug that comes from a plant source. Digoxin is used to treat problems with heart rhythms or heart failure. Psyllium, the ingredient in Metamucil© used to add fiber to a patient's diet, is also a natural product. Taxol®, made from a type of tree bark, is used to treat cancer.
    [Show full text]
  • PDF-Document
    Figure S1. Chromatogram of 66 compounds at 0.05 mg L-1 Figure S2. Example of chromatogram and mass spectra in sample (S-162, sennosides) Table S1. Selection criteria of 66 target compounds based on Korean legislation. Not Not Prohibited Prohibited Compounds Pharmaceutical authorized Compounds Pharmaceutical authorized compounds1) compounds1) ingredients2) ingredients2) 2,4-Dinitrophenol (2,4-DNP) Ο Liothyronine Ο Ο 7-keto-dehydroepiandrosterone (7-keto-DHEA) Ο Lorcaserine Ο Amphetamine Ο Lovastatin Ο Asarone Ο Magnoflorine Ο Atropine Ο Melatonin Ο Berberine Ο Metformin Ο beta-methylphenethylamine (BMPEA) Ο Methylclothiazide Ο Bisacodyl Ο Mexamine (5-methoxytryptamine) Ο Buformin Ο N-nitrosofenfluramine Ο Ο Cascaroside A Ο Ο Noopept Ο Cascaroside B Ο Ο Oxilofrine Ο Cascaroside C Ο Ο Oxindole Ο Cascaroside D Ο Ο Oxitriptan (5-hydroxytryptohpane) Ο Chlorothiazide Ο Phendimetrazine Ο Cimifugin Ο Phenformin Ο Dehydroepiandrosterone (DHEA) Ο Phenolphtalein Ο Ο Echinacoside Ο Phentermine Ο Ephedrine Ο Ο Picamilon Ο Fenfluramine Ο Ο Rauwolscine (α-yohimbine) Ο Ο Fluoxetine Ο Ο Reserpine Ο Glibenclamide Ο Ο Salbutamol Ο Gliclazide Ο Ο Salicin Ο Glimepiride Ο Ο Salicylic acid Ο Glipizide Ο Ο Scopolamine Ο Hesperidin Ο Sennoside A Ο Ο Hydrastine Ο Sennoside B Ο Ο Hydrochlorothiazide Ο Serotonin (5-hydroxytryptamine) Ο Hydroflumethiazide Ο Synephrine Ο Icariin Ο Ο Tolbutamide Ο Icaritin Ο Trichloromethiazide Ο Kavain Ο Trigonelline Ο Levodopa Ο Vinpocetine Ο Levothyroxine Ο Ο Yohimbine (β-yohimbine) Ο Ο 1) Prohibited by Food and Sanitation Act in Ministry of Food and Drug Safety in Korea 2) Not authorized food ingredients by Food Code in Korea Table S2.
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]
  • Prospectives of Helicobacter Pylori
    Sys Rev Pharm 2021; 12(8): 460-465 Review Article A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453 Research Article Prospectives of Helicobacter pylori S Manodhini Elakkiya*, R Sambath Kumar, N Venkateswaramurthy Department of pharmaceutics, JKK Nattraja College of Pharmacy, Tamil Nadu, India Article History: Submitted: 26.04.2021 Accepted: 10.05.2021 Published: 17.05.2021 ABSTRACT creasing prevalence of resistant strains of H. pylori and achieve a >90% eradication rate. Although treatment Helicobacter pylori is a gram negative bacteria (H. pylori) regimens provide acceptable eradication rates, whose infection is highly prevalent among the human H. pylori the regimens used should contribute to future resis- population and leads to gastrointestinal tract related tance of diseases (gastric and duodenal ulcers, mucosa asso- H. pylori to antimicrobials and other therapies. ciated tissue lymphoma and gastric adenocarcinoma). infection will never have any Most people with H. pylori Keywords: Helicobacter pylori, Route of transmission, signs or symptoms. While this bacterium infects 50% Thumb rules, Treatment regimen of the world’s population, in Africa its prevalence reach as high as 80% as the infection is acquired during child- hood. H. pylori eradication treatment is becoming more *Correspondence: S Manodhini Elakkiya, Department challenging due to increasing antimicrobial resistance. of Pharmaceutics, JKK Nattraja College of Pharmacy, Treatment regimens are expected to overcome the in- Tamil Nadu, India, E-mail: [email protected] INTRODUCTION ents or siblings and they are also affected due to the transmission Helicobacter pylori (H. pylori), previously known as Campylo- of the bacterium to the GI tract by oral cavity, by fecal-oral route bacter pylori, are a spiral shaped bacteria which is indicated by or by human to human transmission (Zhao S, et al., 2014; Safavi the term ‘Helico’.
    [Show full text]
  • Hydrastis Canadensis) on BACTERIAL MULTI DRUG RESISTANT EFFLUX PUMPS Jyothi Rangineni Clemson University, [email protected]
    Clemson University TigerPrints All Dissertations Dissertations 8-2011 EFFECT OF GOLDENSEAL (Hydrastis canadensis) ON BACTERIAL MULTI DRUG RESISTANT EFFLUX PUMPS Jyothi Rangineni Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations Part of the Microbiology Commons Recommended Citation Rangineni, Jyothi, "EFFECT OF GOLDENSEAL (Hydrastis canadensis) ON BACTERIAL MULTI DRUG RESISTANT EFFLUX PUMPS" (2011). All Dissertations. 785. https://tigerprints.clemson.edu/all_dissertations/785 This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, please contact [email protected]. EFFECT OF GOLDENSEAL (Hydrastis canadensis) ON BACTERIAL MULTI DRUG RESISTANT EFFLUX PUMPS A Dissertation Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy Microbiology by Jyothi Rangineni December 2009 Accepted by: Dr. Tzuen-Rong Tzeng, Committee Chair Dr. Joseph Gangemi Dr. Xiuping Jiang Dr. Melissa Riley Abstract Multi-Drug-Resistance (MDR) efflux pumps have been increasingly reported in Gram negative and Gram positive bacteria. These efflux mechanisms pump out a wide variety of structurally unrelated antimicrobials thus leading to reduced susceptibility due to lowered intracellular concentrations. The activity of such antimicrobials can be restored by the inhibition of the multi-drug efflux pumps. Several MDR pump inhibitors which inhibit the efflux mechanisms in bacteria have been identified. Reserpine and verapamil are two such inhibitors showing considerable effects on the MDR pumps. But the concentrations required to achieve these effects are too high to be clinically relevant.
    [Show full text]
  • ACMT 2020 Annual Scientific Meeting Abstracts – New York, NY
    Journal of Medical Toxicology https://doi.org/10.1007/s13181-020-00759-7 ANNUAL MEETING ABSTRACTS ACMT 2020 Annual Scientific Meeting Abstracts – New York, NY Abstract: These are the abstracts of the 2020 American College of Background: Oral cyanide is a potentially deadly poison and has the Medical Toxicology (ACMT) Annual Scientific Meeting. Included here potential for use by terrorists. There is potential for a mass casualty ex- are 174 abstracts that will be presented in March 2020, including research posure scenario, and currently, there are no FDA-approved antidotes spe- studies from around the globe and the ToxIC collaboration, clinically cifically for oral cyanide poisoning. significant case reports describing new toxicologic phenomena, and en- Hypothesis: We hypothesize that animals treated with oral sodium thio- core research presentations from other scientific meetings. sulfate will have a higher rate of survival vs. control in a large animal model of acute, severe, oral cyanide toxicity. Keywords Abstracts, Annual Scientific Meeting, Toxicology Methods: This is a prospective study that took place at the University of Investigators Consortium, Medical Toxicology Foundation Colorado Anschutz Medical Campus. Nine swine (45–55 kg) were in- strumented, sedated, and stabilized. Potassium cyanide (8 mg/kg KCN) in Correspondence: American College of Medical Toxicology (ACMT), saline was delivered as a one-time bolus via an orogastric tube. Three 10645 N. Tatum Blvd, Phoenix, AZ, USA; [email protected] minutes after cyanide, animals who were randomized to the treatment group received sodium thiosulfate (508.2 mg/kg, 3.25 M solution) via Introduction: The American College of Medical Toxicology (ACMT) re- orogastric tube.
    [Show full text]
  • Review on Plant Antimicrobials: a Mechanistic Viewpoint Bahman Khameneh1, Milad Iranshahy2,3, Vahid Soheili1 and Bibi Sedigheh Fazly Bazzaz3*
    Khameneh et al. Antimicrobial Resistance and Infection Control (2019) 8:118 https://doi.org/10.1186/s13756-019-0559-6 REVIEW Open Access Review on plant antimicrobials: a mechanistic viewpoint Bahman Khameneh1, Milad Iranshahy2,3, Vahid Soheili1 and Bibi Sedigheh Fazly Bazzaz3* Abstract Microbial resistance to classical antibiotics and its rapid progression have raised serious concern in the treatment of infectious diseases. Recently, many studies have been directed towards finding promising solutions to overcome these problems. Phytochemicals have exerted potential antibacterial activities against sensitive and resistant pathogens via different mechanisms of action. In this review, we have summarized the main antibiotic resistance mechanisms of bacteria and also discussed how phytochemicals belonging to different chemical classes could reverse the antibiotic resistance. Next to containing direct antimicrobial activities, some of them have exerted in vitro synergistic effects when being combined with conventional antibiotics. Considering these facts, it could be stated that phytochemicals represent a valuable source of bioactive compounds with potent antimicrobial activities. Keywords: Antibiotic-resistant, Antimicrobial activity, Combination therapy, Mechanism of action, Natural products, Phytochemicals Introduction bacteria [10, 12–14]. However, up to this date, the Today’s, microbial infections, resistance to antibiotic structure-activity relationships and mechanisms of action drugs, have been the biggest challenges, which threaten of natural compounds have largely remained elusive. In the health of societies. Microbial infections are responsible the present review, we have focused on describing the re- for millions of deaths every year worldwide. In 2013, 9.2 lationship between the structure of natural compounds million deaths have been reported because of infections and their possible mechanism of action.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tinnitus
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tinnitus Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-AROMOLINE 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-HERNANDEZINE 2 (+)-ISOLARICIRESINOL 1 (+)-NORTRACHELOGENIN 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 1 (-)-ANABASINE 1 (-)-APOGLAZIOVINE 1 (-)-BETONICINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-CANADINE 1 (-)-DICENTRINE 1 (-)-EPICATECHIN 2 (-)-EPIGALLOCATECHIN-GALLATE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 Chemical Activity Count 1-ETHYL-BETA-CARBOLINE 2 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 10-DEHYDROGINGERDIONE 1 10-GINGERDIONE 1 12-(4'-METHOXYPHENYL)-DAURICINE 1 12-METHOXYDIHYDROCOSTULONIDE 1 13',II8-BIAPIGENIN 1 13-HYDROXYLUPANINE 1 13-OXYINGENOL-ESTER 1 16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 16-HYDROXY-4,4,10,13-TETRAMETHYL-17-(4-METHYL-PENTYL)-HEXADECAHYDRO- 1 CYCLOPENTA[A]PHENANTHREN-3-ONE 16-HYDROXYINGENOL-ESTER 1 2'-O-GLYCOSYLVITEXIN 1 2-BETA,3BETA-27-TRIHYDROXYOLEAN-12-ENE-23,28-DICARBOXYLIC-ACID 1 2-METHYLBUT-3-ENE-2-OL 2 2-VINYL-4H-1,3-DITHIIN 1 20-DEOXYINGENOL-ESTER 1 22BETA-ESCIN 1 24-METHYLENE-CYCLOARTANOL 2 3,3'-DIMETHYLELLAGIC-ACID 1 3,4-DIMETHOXYTOLUENE 2 3,4-METHYLENE-DIOXYCINNAMIC-ACID-BORNYL-ESTER 1 3,4-SECOTRITERPENE-ACID-20-EPI-KOETJAPIC-ACID
    [Show full text]